CRISM Therapeutics (CRTX) Share Price, News & Analysis

Company Overview

CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.

Key Stats

• Today's Range: 11 to 12
• 50-Day Range: 8 to 12
• 52-Week Range: 5 to 30.90
• Volume: 6,254 shs
• Average Volume: 90,690 shs
• Market Capitalization: £3.59 million
• P/E Ratio: 1.34
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed this year?

CRISM Therapeutics' stock was trading at GBX 11.90 on January 1st, 2024. Since then, CRTX shares have decreased by 7.6% and is now trading at GBX 11.
View the best growth stocks for 2024 here.

How do I buy shares of CRISM Therapeutics?

Shares of CRTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Basic Materials
• Industry: Other Industrial Metals & Mining
• Sub-Industry: N/A
• Current Symbol: LON:CRTX
• CUSIP: N/A
• CIK: N/A
• Web: www.crismtherapeutics.com
• Phone: N/A
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 8.22
• Trailing P/E Ratio: 1.34
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,770,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.67%
• Return on Assets: -26.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.56
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 6 per share
• Price / Book: 1.83

Miscellaneous

• Outstanding Shares: 32,680,000
• Free Float: N/A
• Market Cap: £3.59 million
• Optionable: N/A
• Beta: 0.81